About Psilocybin Therapy
An overview of investigational psilocybin therapy and how it is being studied for mental health conditions. It explains the treatment process, including preparation, the dosing session, and integration.
Provider
Details
Enrollment
Course Overview
This page explains investigational psilocybin therapy, also described as psilocybin treatment, and how it is being studied with psychological support for certain mental health conditions. It notes that COMPASS Pathways has developed an investigational synthesised formulation of psilocybin called COMP360. The content covers what happens during psilocybin therapy, including preparation, the dosing session, and integration afterward. It describes the session environment, the role of the therapist, and the use of music and an eye mask during the experience. The page is primarily informational and also outlines COMPASS Pathways’ clinical development programme and the conditions being researched, including treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa.
Who is this for?
People seeking an overview of investigational psilocybin therapy, including those interested in mental health research and treatment development.
About the Provider
COMPASS Pathways plc (Nasdaq: CMPS) is a UK-headquartered clinical-stage biopharmaceutical company and the most advanced developer of a classic psychedelic medicine. Its lead asset, COMP360 — a synthetic, proprietary formulation of psilocybin — is being developed for treatment-resistant depression (TRD) delivered alongside a psychological-support model. COMP360 is the first psilocybin programme to complete two positive pivotal Phase 3 trials: COMP005 met its primary endpoint in June 2025 and the confirmatory COMP006 (two fixed doses given three weeks apart) did so in February 2026, with 26-week data reported in July 2026 confirming a rapid and durable antidepressant profile. In April 2026 the FDA granted a rolling NDA submission request and selected COMP360 for the Commissioner's National Priority Voucher programme, which carries a shortened review window. COMPASS has since begun that rolling submission and guides to a potential US launch in the first half of 2027, subject to approval, positioning it as the frontrunner for the first FDA-approved classic psychedelic therapy.
View COMPASS Pathways profileCourse Details
- PricePrice on request
- FormatSelf-paced
- Lifecycle statusDiscontinued
- SkillsIntegrationPsilocybin TherapyMusic and Set/SettingUnderstanding investigational psilocybin therapyLearning the basic treatment processReviewing current areas of clinical researchUnderstand investigational psilocybin therapyDescribe the preparation, dosing, and integration processRecognize the role of psychological support in treatmentIdentify the session environment and support elementsAwareness of therapy session structureUnderstanding preparation, dosing, and integrationFamiliarity with clinical research in mental healthDescribe the psilocybin treatment process